Abstract
Purpose
Lung cancer and mesothelioma are two types of respiratory disease that have fatal courses and poor prognoses. Although a substantial number of targeted small molecules and antibody drugs have been developed, the 5-year survival rates of these patients remain relatively low. Moreover, most patients inevitably develop clinical resistance to treatment. Therefore, novel therapeutic options and cancer prognostic biomarkers are urgently needed.
Methods
In this review, we summarized the recent literature from various electronic databases, including PubMed, and highlighted the most advanced findings regarding the hippo pathway in lung cancer and mesothelioma.
Conclusion
The hippo signaling transduction pathway has been demonstrated to play crucial roles in lung cancer and mesothelioma pathogenesis, including tumor development and multidrug resistance, and is emerging as a promising therapeutic target, potentially providing new tools for the detection of these tumors at an early stage.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Agathanggelou A, Honorio S, Macartney D et al (2001) Methylation associated inactivation of RASSF1A from region 3p21.3 in lung, breast and ovarian tumours. Oncogene 20:1509–1518. https://doi.org/10.1038/sj.onc.1204175
Aldonza MB, Hong JY, Bae SY et al (2015) Suppression of MAPK signaling and reversal of mTOR-dependent MDR1-associated multidrug resistance by 21alpha-methylmelianodiol in lung cancer cells. PLoS One 10:e0127841. https://doi.org/10.1371/journal.pone.0127841
Altomare DA (2005) A mouse model recapitulating molecular features of human mesothelioma. Cancer Res 65:8090–8095. https://doi.org/10.1158/0008-5472.can-05-2312
Bianchi A, Mitsunaga S, Cheng J et al (1995) High frequency of inactivating mutations in the neurofibromatosis type 2 gene (NF2) in primary malignant mesotheliomas. Proc Natl Acad Sci USA 92:10854–10858
Bora-Singhal N, Nguyen J, Schaal C et al (2015) YAP1 regulates OCT4 Activity and SOX2 expression to facilitate self-renewal and vascular mimicry of stem-like cells. Stem Cells 33:1705–1718. https://doi.org/10.1002/stem.1993
Bui D, Lee W, White A et al (2016) Cytokinesis involves a nontranscriptional function of the Hippo pathway effector YAP. Sci Signal. https://doi.org/10.1126/scisignal.aaa9227
Carbone M, Ly BH, Dodson RF et al (2012) Malignant mesothelioma: facts, myths, and hypotheses. J Cell Physiol 227:44–58. https://doi.org/10.1002/jcp.22724
Chen Y-C, Hsu H-S, Chen Y-W et al (2008) Oct-4 expression maintained cancer stem-like properties in lung cancer-derived CD133-positive cells. PLoS One 3:e2637. https://doi.org/10.1371/journal.pone.0002637
Chen HY, Yu SL, Ho BC et al (2015) R331W missense mutation of oncogene YAP1 Is a Germline risk allele for lung adenocarcinoma with medical actionability. J Clinical Oncol 33:2303–2310. https://doi.org/10.1200/JCO.2014.59.3590
Cheng JQ, Jhanwar SC, Klein WM et al (1994) p16 alterations and deletion mapping of 9p21-p22 in malignant mesothelioma. Cancer Res 54:5547. https://doi.org/10.1200/JCO.2014.59.3590
Dai Y, Jablons D, You L (2017a) Hippo pathway in lung development. J Thorac Dis 9:2246–2250. https://doi.org/10.21037/jtd.2017.07.18
Dai Y, Liu S, Zhang W-Q et al (2017b) YAP1 regulates ABCG2 and cancer cell side population in human lung cancer cells. Oncotarget 8:4096–4109. https://doi.org/10.18632/oncotarget.13686
Das Thakur M, Feng Y, Jagannathan R et al (2010) Ajuba LIM proteins are negative regulators of the hippo signaling pathway. Curr Biol 20:657–662. https://doi.org/10.1016/j.cub.2010. 02.035
David C, Marina Villanueva P, Elizabet A-G et al (2016) AMPK as a target in rare diseases. Curr Drug Targets 17:921–931. https://doi.org/10.2174/1389450117666160112110204
DeRan M, Yang J, Shen C-H et al (2014) Energy stress regulates hippo-YAP signaling involving AMPK-mediated regulation of angiomotin-like 1 protein. Cell Rep 9:495–503. https://doi.org/10.1016/j.celrep.2014.09.036
Donninger H, Vos MD, Clark GJ (2007) The RASSF1A tumor suppressor. J Cell Sci 120:3163–3172. https://doi.org/10.1242/jcs.010389
Donninger H, Clark J, Rinaldo F et al (2015) The RASSF1A tumor suppressor regulates XPA-mediated DNA repair. Mol Cell Biol 35:277–287. https://doi.org/10.1128/mcb.00202-14
Du X, Yu A, Tao W (2014) The non-canonical Hippo/Mst pathway in lymphocyte development and functions. Acta Biochim Biophys Sin 47:60–64. https://doi.org/10.1093/abbs/gmu112
Dubois F, Keller M, Calvayrac O et al (2016) RASSF1A suppresses the invasion and metastatic potential of human non-small cell lung cancer cells by inhibiting YAP activation through the GEF-H1/RhoB pathway. Cancer Res 76:1627–1640. https://doi.org/10.1158/0008-5472.CAN-15-1008
Eramo A, Lotti F, Sette G et al (2007) Identification and expansion of the tumorigenic lung cancer stem cell population. Cell Death Differ 15:504–514. https://doi.org/10.1038/sj.cdd.4402283
Fujii M, Toyoda T, Nakanishi H et al (2012) TGF-β synergizes with defects in the Hippo pathway to stimulate human malignant mesothelioma growth. J Exp Med 209:479–494.https://doi.org/10.1084/jem.20111653
Ganem Neil J, Cornils H, Chiu S-Y et al (2014) Cytokinesis failure triggers hippo tumor suppressor pathway activation. Cell 158:833–848. https://doi.org/10.1016/j.cell.2014.06.029
Gao X, Le X, Costa DB (2016) The safety and efficacy of osimertinib for the treatment of EGFR T790M mutation positive non-small-cell lung cancer. Expert Rev Anticancer Ther 16:383–390. https://doi.org/10.1586/14737140.2016.1162103
Gazdar AF (2009) Personalized medicine and inhibition of EGFR signaling in lung cancer. N Engl J Med 361:1018–1020. https://doi.org/10.1056/NEJMe0905763
Holt SV, Logie A, Davies BR et al (2012) Enhanced apoptosis and tumor growth suppression elicited by combination of MEK (selumetinib) and mTOR kinase inhibitors (AZD8055). Cancer Res 72:1804–1813. https://doi.org/10.1158/0008-5472.CAN-11-1780
Hsu P-C, You B, Yang Y-L et al (2016) YAP promotes erlotinib resistance in human non-small cell lung cancer cells. Oncotarget 7:51922–51933. https://doi.org/10.18632/oncotarget.10458
Huang C-P, Tsai M-F, Chang T-H et al (2013) ALDH-positive lung cancer stem cells confer resistance to epidermal growth factor receptor tyrosine kinase inhibitors. Cancer Lett 328:144–151. https://doi.org/10.1016/j.canlet.2012.08.021
Hurwitz JL, Scullin P, Campbell L (2011) Afatinib treatment in advanced non-small cell lung cancer. Lung Cancer 2:47–57. https://doi.org/10.2147/LCTT.S16310
Jemal A, Siegel R, Ward E et al (2006) Cancer statistics, 2006. CA Cancer J Clin 56:106–130. https://doi.org/10.3322/canjclin.56.2.106
Jiang L, Akatsuka S, Nagai H et al (2012) Iron overload signature in chrysotile-induced malignant mesothelioma. J Pathol 228:366–377. https://doi.org/10.1002/path.4075
Jin A, Neufeld TP, Choe J (2015) Kibra and aPKC regulate starvation-induced autophagy in Drosophila. Biochem Biophys Res Commun 468:1–7. https://doi.org/10.1016/j.bbrc.2015.11.011
Joffre C, Dupont N, Hoa L et al (2015) The pro-apoptotic STK38 kinase is a new Beclin1 partner positively regulating autophagy. Curr Biol 25:2479–2492. https://doi.org/10.1016/j.cub2015.08.031
Kakiuchi T, Takahara T, Kasugai Y et al (2016) Modeling mesothelioma utilizing human mesothelial cells reveals involvement of phospholipase-C beta 4 in YAP-active mesothelioma cell proliferation. Carcinogenesis. https://doi.org/10.1093/carcin/bgw084
Katagiri K, Katakai T, Ebisuno Y et al (2009) Mst1 controls lymphocyte trafficking and interstitial motility within lymph nodes. EMBO J 28:1319–1331. https://doi.org/10.1038/emboj.2009.82
Kim JM, Kang DW, Long LZ et al (2011) Differential expression of Yes-associated protein is correlated with expression of cell cycle markers and pathologic TNM staging in non small-cell lung carcinoma. Hum Pathol 42:315–323. https://doi.org/10.1016/j.humpath.2010.08.003
Kohno T, Nakaoku T, Tsuta K et al (2015) Beyond ALK-RET, ROS1 and other oncogene fusions in lung cancer. Transl Lung Cancer Res 4:156–164. https://doi.org/10.3978/j.issn2218-6751.2014.11.11
Lau AN, Curtis SJ, Fillmore CM et al (2014) Tumor-propagating cells and Yap/Taz activity contribute to lung tumor progression and metastasis. EMBO J 33:468–481. https://doi.org/10.1002/embj201386082
Lee JE, Park HS, Lee D et al (2016) Hippo pathway effector YAP inhibition restores the sensitivity of EGFR-TKI in lung adenocarcinoma having primary or acquired EGFR-TKI resistance. Biochem Biophys Res Commun 474:154–160. https://doi.org/10.1016/j.bbrc.2016.04.089
Levy D, Adamovich Y, Reuven N et al (2008) Yap1 phosphorylation by c-Abl Is a critical step in selective activation of proapoptotic genes in response to DNA damage. Mol Cell 29:350–361. https://doi.org/10.1016/j.molcel.2007.12.022
Li D, Wei L, Xu B et al (2014) Association of GWAS-identified lung cancer susceptibility loci with survival length in patients with small-cell lung cancer treated with platinum-based chemotherapy. PLoS One 9:e113574. https://doi.org/10.1371/journal.pone.0113574
Liang N, Zhang C, Dill P et al (2014) Regulation of YAP by mTOR and autophagy reveals a therapeutic target of tuberous sclerosis complex. J Exp Med 211:2249–2263. https://doi.org/10.1084/jem.20140341
Lin XY, Zhang XP, Wu JH et al (2014) Expression of LATS1 contributes to good prognosis and can negatively regulate YAP oncoprotein in non-small-cell lung cancer. Tumour Biol 35:6435–6443. https://doi.org/10.1007/s13277-014-1826-z
Liu X, Cho WC (2017) Precision medicine in immune checkpoint blockade therapy for non-small cell lung cancer. Clin Transl Med 6:7. https://doi.org/10.1186/s40169-017-0136-7
Luo SY, Sit K-Y, Sihoe A et al (2014) Aberrant large tumor suppressor 2 (LATS2) gene expression correlates with EGFR mutation and survival in lung adenocarcinomas. Lung Cancer 85:282–292. https://doi.org/10.1016/j.lungcan.2014.05.025
Maejima Y, Kyoi S, Zhai P et al (2013) Mst1 inhibits autophagy by promoting the interaction between Beclin1 and Bcl-2. Nat Med 19:1478–1488. https://doi.org/10.1038/nm.3322
Mahoney J, Mori M, Szymaniak A et al (2014) The hippo pathway effector Yap controls patterning and differentiation of airway epithelial progenitors. Dev Cell 30:137–150. https://doi.org/10.1016/j.devcel.2014.06.003
Makita R, Uchijima Y, Nishiyama K et al (2008) Multiple renal cysts, urinary concentration defects, and pulmonary emphysematous changes in mice lacking TAZ. Am J Physiol Renal Physiol 294:F542–F553. https://doi.org/10.1152/ajprenal.00201.2007
Meerang M, Berard K, Friess M et al (2016) Low merlin expression and high survivin labeling index are indicators for poor prognosis in patients with malignant pleural mesothelioma. Mol Oncol 10:1255–1265. https://doi.org/10.1016/j.molonc.2016.06.005
Miyanaga A, Masuda M, Tsuta K et al (2015) Hippo pathway gene mutations in malignant mesothelioma: revealed by RNA and targeted exon sequencing. J Thorac Oncol 10:844–851. https://doi.org/10.1097/jto.0000000000000493
Mizuno T, Murakami H, Fujii M et al (2012) YAP induces malignant mesothelioma cell proliferation by upregulating transcription of cell cycle-promoting genes. Oncogene 31:5117–5122. https://doi.org/10.1038/onc.2012.5
Mo J-S, Meng Z, Kim YC et al (2015) Cellular energy stress induces AMPK-mediated regulation of YAP and the hippo pathway. Nat Cell Biol 17:500–510. https://doi.org/10.1038/ncb3111
Moroishi T, Hayashi T, Pan W-W et al (2016) The hippo pathway kinases LATS1/2 suppress cancer immunity. Cell 167:1525–1539.e1517. https://doi.org/10.1016/j.cell.2016.11.005
Mukai S, Yabuta N, Yoshida K et al (2015) Lats1 suppresses centrosome overduplication by modulating the stability of Cdc25B. Sci Rep 5:16173. https://doi.org/10.1038/srep16173
Murakami H, Mizuno T, Taniguchi T et al (2011) LATS2 Is a tumor suppressor gene of malignant mesothelioma. Cancer Res 71:873–883. https://doi.org/10.1158/0008-5472.can-10-2164
Napoletano F, Occhi S, Calamita P et al (2011) Polyglutamine atrophin provokes neurodegeneration in Drosophila by repressing fat. EMBO J 30:945–958. https://doi.org/10.1038/emboj.2011.1
Nichols J, Zevnik B, Anastassiadis K et al (1998) Formation of pluripotent stem cells in the mammalian embryo depends on the POU transcription factor Oct4. Cell 95:379–391. https://doi.org/10.1016/S0092-8674(00)81769-9
Nishikimi A, Ishihara S, Ozawa M et al (2014) Rab13 acts downstream of the kinase Mst1 to to deliver the integrin LFA-1 to the cell surface for lymphocyte trafficking. Sci Signal. https://doi.org/10.1126/scisignal.2005199
Noto A, De Vitis C, Pisanu ME et al (2017) Stearoyl-CoA-desaturase 1 regulates lung cancer stemness via stabilization and nuclear localization of YAP/TAZ. Oncogene. https://doi.org/10.1038/onc.2017.75
Paez JG, Jänne PA, Lee JC et al (2004) EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 304:1497–1500. https://doi.org/10.1126/science.1099314
Pao W, Miller V, Zakowski M et al (2004) EGF receptor gene mutations are common in lung cancers from “never smokers” and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci USA 101:13306–13311. https://doi.org/10.1073/pnas.0405220101
Poon CL, Zhang X, Lin JI et al (2012) Homeodomain-interacting protein kinase regulates Hippo pathway-dependent tissue growth. Curr Biol 22:1587–1594. https://doi.org/10.1016/j.cub.2012.06.075
Reuven N, Adler J, Meltser V et al (2013) The Hippo pathway kinase Lats2 prevents DNA damage-induced apoptosis through inhibition of the tyrosine kinase c-Abl. Cell Death Differ 20:1330–1340. https://doi.org/10.1038/cdd.2013.83
Reuven N, Adler J, Porat Z et al (2015) The Tyrosine kinase c-Abl promotes homeodomain-interacting protein kinase 2 (HIPK2) accumulation and activation in response to DNA damage. J Biol Chem 290:16478–16488. https://doi.org/10.1074/jbc.M114.628982
Rho JK, Choi YJ, Kim SY et al (2014) MET and AXL inhibitor NPS-1034 exerts efficacy against lung cancer cells resistant to EGFR kinase inhibitors because of MET or AXL activation. Cancer Res 74:253. https://doi.org/10.1158/0008-5472.CAN-13-1103
Rothschild SI, Gautschi O (2013) Crizotinib in the treatment of non-small-cell lung cancer. Clin Lung Cancer 14:473–480. https://doi.org/10.1016/j.cllc.2013.04.006
Santarpia M, Altavilla G, Rosell R (2015) Alectinib: a selective, next-generation ALK inhibitor for treatment of ALK-rearranged non-small-cell lung cancer. Expert Rev Respir Med 9:255–268. https://doi.org/10.1586/17476348.2015.1009040
Sekido Y (2010) Genomic abnormalities and signal transduction dysregulation in malignant mesothelioma cells. Cancer Sci 101:1–6. https://doi.org/10.1111/j.1349-7006.2009.01336.x
Senovilla L, Vitale I, Martins I et al (2012) An immunosurveillance mechanism controls cancer cell ploidy. Science 337:1678–1684. https://doi.org/10.1126/science.1224922
Sequist LV, Waltman BA, Dias-Santagata D et al (2011) Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors. Sci Transl Med 3:75ra26. https://doi.org/10.1126/scitranslmed.3002003
Shien K, Toyooka S, Yamamoto H et al (2013) Acquired resistance to EGFR inhibitors is associated with a manifestation of stem cell–like properties in cancer cells. Cancer Res 73:3051–3061. https://doi.org/10.1158/0008-5472.CAN-12-4136
Shigematsu H, Gazdar AF (2006) Somatic mutations of epidermal growth factor receptor signaling pathway in lung cancers. Int J Cancer 118:257–262. https://doi.org/10.1002/ijc.21496
Singh S, Trevino J, Bora-Singhal N et al (2012) EGFR/Src/Akt signaling modulates Sox2 expression and self-renewal of stem-like side-population cells in non-small cell lung cancer. Mol Cancer 11:73. https://doi.org/10.1186/1476-4598-11-73
Tanaka H, Hayashi A, Morimoto T et al (2012) A case of lung adenocarcinoma harboring EGFR mutation and EML4-ALK fusion gene. BMC Cancer 12:558. https://doi.org/10.1186/1471-2407-12-558
Tanaka I, Osada H, Fujii M et al (2015) LIM-domain protein AJUBA suppresses malignant mesothelioma cell proliferation via Hippo signaling cascade. Oncogene 34:73–83. https://doi.org/10.1038/onc.2013.528
Tanaka K, Osada H, Murakami-Tonami Y et al (2017) Statin suppresses hippo pathway-inactivated malignant mesothelioma cells and blocks the YAP/CD44 growth stimulatory axis. Cancer Lett 385:215–224. https://doi.org/10.1016/j.canlet.2016.10.020
Tang Y, Hou J, Li G et al (2014) ABCG2 regulates the pattern of self-renewing divisions in cisplatin-resistant non-small cell lung cancer cell lines. Oncol Rep 32:2168–2174. https://doi.org/10.3892/or.2014.3470
Tang F, Gill J, Ficht X et al (2015) The kinases NDR1_2 act downstream of the Hippo homolog MST1 to mediate both egress of thymocytes from the thymus and lymphocyte motility. Sci Signal 8:ra100. https://doi.org/10.1126/scisignal.aab2425
Taniguchi T, Karnan S, Fukui T et al (2007) Genomic profiling of malignant pleural mesothelioma with array-based comparative genomic hybridization shows frequent non-random chromosomal alteration regions including JUN amplification on 1p32. Cancer Sci 98: 438–446. https://doi.org/10.1111/j.1349-7006.2006.00386.x
Testa JR, Cheung M, Pei J et al (2011) Germline BAP1 mutations predispose to malignant mesothelioma. Nat Genet 43:1022–1025. https://doi.org/10.1038/ng.912
Tiseo M, Gelsomino F, Boggiani D et al (2011) EGFR and EML4-ALK gene mutations in NSCLC: a case report of erlotinib-resistant patient with both concomitant mutations. Lung cancer 71:241–243. https://doi.org/10.1016/j.lungcan.2010.11.014
Toji S, Yabuta N, Hosomi T et al (2004) The centrosomal protein Lats2 is a phosphorylation target of Aurora-A kinase. Genes Cells 9:383–397. https://doi.org/10.1111/j.1356-9597.2004.00732.x
Toyokuni S (1996) Iron-induced carcinogenesis: the role of redox regulation. Free Radic Biol Med 20:553–566. https://doi.org/10.1016/0891-5849(95)02111-6
Tranchant R, Quetel L, Tallet A et al (2016) Co-occurring mutations of tumor suppressor genes, LATS2 and NF2, in malignant pleural mesothelioma. Clin Cancer Res 23:3191–3202. https://doi.org/10.1158/1078-0432.CCR-16-1971
Tricker EM, Xu C, Uddin S et al (2015) Combined EGFR/MEK inhibition prevents the emergence of resistance in EGFR mutant lung cancer. Cancer Discov 5:960–971. https://doi.org/10.1158/2159-8290.CD-15-0063
Ueda Y, Katagiri K, Tomiyama T et al (2012) Mst1 regulates integrin-dependent thymocyte trafficking and antigen recognition in the thymus. Nat Commun 3:1098. https://doi.org/10.1038/ncomms2105
Wang L, Chen Z, Wang Y et al (2014) WWTR1 promotes cell proliferation and inhibits apoptosis through cyclin A and CTGF regulation in non-small cell lung cancer. Tumour Biol 35:463–468. https://doi.org/10.1007/s13277-013-1064-9
Wang W, Xiao Z-D, Li X et al (2015) AMPK modulates Hippo pathway activity to regulate energy homeostasis. Nat Cell Biol 17:490–499. https://doi.org/10.1038/ncb3113
Wilkinson D, Jariwala J, Anderson E et al (2015) Phosphorylation of LC3 by the hippo kinases STK3/STK4 is essential for autophagy. Mol Cell 57:55–68. https://doi.org/10.1016/j.molcel.2014.11.019
Wu S, Huang J, Dong J et al (2003) hippo encodes a Ste-20 family protein kinase that restricts cell proliferation and promotes apoptosis in conjunction with salvador and warts. Cell 114:445–456. https://doi.org/10.1016/S0092-8674(03)00549-X
Wu C, Xu B, Yuan P et al (2010) Genome-wide interrogation identifies YAP1 variants associated with survival of small-cell lung cancer patients. Cancer Res 70:9721–9729. https://doi.org/10.1158/0008-5472.CAN-10-1493
Xie M, Zhang L, He CS et al (2012) Prognostic significance of TAZ expression in resected non-small cell lung cancer. J Thorac Oncol 7:799–807. https://doi.org/10.1097/JTO.0b013e318248240b
Xu CM, Liu WW, Liu CJ et al (2013) Mst1 overexpression inhibited the growth of human non-small cell lung cancer in vitro and in vivo. Cancer gene Ther 20:453–460. https://doi.org/10.1038/cgt.2013.40
Xu W, Wei Y, Wu S et al (2015) Up-regulation of the Hippo pathway effector TAZ renders lung adenocarcinoma cells harboring EGFR-T790M mutation resistant to gefitinib. Cell Biosci 5:7. https://doi.org/10.1186/2045-3701-5-7
Xu YJ, Du Y, Fan Y (2016) Long noncoding RNAs in lung cancer: what we know in 2015. Clin Transl Oncol 18:660–665. https://doi.org/10.1007/s12094-015-1448-y
Yabuta N, Mukai S, Okada N et al (2011) The tumor suppressor Lats2 is pivotal in aurora A and aurora B signaling during mitosis. Cell Cycle 10:2724–2736. https://doi.org/10.4161/cc.10.16.16873
Yabuta N, Yoshida K, Mukai S et al (2016) Large tumor suppressors 1 and 2 regulate aurora-B through phosphorylation of INCENP to ensure completion of cytokinesis. Heliyon 2:e00131. https://doi.org/10.1016/j.heliyon.2016.e00131
Yeung B, Yu J, Yang X (2016) Roles of the Hippo pathway in lung development and tumorigenesis. Int J Cancer 138:533–539. https://doi.org/10.1002/ijc.29457
Yin F, Yu J, Zheng Y et al (2013) Spatial organization of hippo signaling at the plasma membrane mediated by the tumor suppressor Merlin/NF2. Cell 154:1342–1355. https://doi.org/10.1016/j.cell.2013.08.025
Yokoyama T, Osada H, Murakami H et al (2008) YAP1 is involved in mesothelioma development and negatively regulated by Merlin through phosphorylation. Carcinogenesis 29:2139–2146. https://doi.org/10.1093/carcin/bgn200
You B, Yang Y-L, Xu Z et al (2015) Inhibition of ERK1/2 down-regulates the Hippo/YAP signaling pathway in human NSCLC cells. Oncotarget 6:4357–4368. https://doi.org/10.18632/oncotarget.2974
Zhang Z, Lee JC, Lin L et al (2012) Activation of the AXL kinase causes resistance to EGFR-targeted therapy in lung cancer. Nat Genet 44:852–860. https://doi.org/10.1038/ng.2330
Zhang W, Gao Y, Li P et al (2014) VGLL4 functions as a new tumor suppressor in lung cancer by negatively regulating the YAP-TEAD transcriptional complex. Cell Res 24:331–343. https://doi.org/10.1038/cr.2014.10
Zhang W, Gao Y, Li F et al (2015) YAP promotes malignant progression of Lkb1-deficient lung adenocarcinoma through downstream regulation of survivin. Cancer Res 75:4450. https://doi.org/10.1158/0008-5472.CAN-14-3396
Zhang L, Huang Y, Zhuo W et al (2016a) Fisetin, a dietary phytochemical, overcomes Erlotinib-resistance of lung adenocarcinoma cells through inhibition of MAPK and AKT pathways. Am J Transl Res 8:4857–4868
Zhang Y, He R-Q, Dang Y-W et al (2016b) Comprehensive analysis of the long noncoding RNA HOXA11-AS gene interaction regulatory network in NSCLC cells. Cancer Cell Int 16:89. https://doi.org/10.1186/s12935-016-0366-6
Zhou Z, Hao Y, Liu N et al (2011) TAZ is a novel oncogene in non-small cell lung cancer. Oncogene 30:2181–2186. https://doi.org/10.1038/onc.2010.606
Acknowledgements
This research was supported by the National Natural Science Foundation of China (81728012), the Natural Science Foundation of Zhejiang Province (LY18H160065), the Zhejiang Medical and Health Science and Technology Plan Project (2018260845), the Zhejiang Xinmiao Talents Program (2017R406050), the Science Foundation of Zhejiang Sci-Tech University (14042107-Y), and the Graduate Research and Innovation Projects of Zhejiang Sci-Tech University (YCX16036), China.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
These authors declare no conflicts of interest.
Ethical approval
This article does not contain any studies with human participants or animals performed by any of the authors.
Rights and permissions
About this article
Cite this article
Liu, XL., Zuo, R. & Ou, WB. The hippo pathway provides novel insights into lung cancer and mesothelioma treatment. J Cancer Res Clin Oncol 144, 2097–2106 (2018). https://doi.org/10.1007/s00432-018-2727-0
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00432-018-2727-0